← All trials
NCT03942224
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2020
- Primary completion
- May 30, 2025
- Completion date
- May 30, 2025
- First posted
- —
- Last posted
- —
- Enrollment
- 76
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Emory UniversityLead sponsor
- Janssen Pharmaceutica NVCollaborator
- Emory UniversityOverall official - principal investigator
- Emory UniversityReponsible party - principal investigator
- TakedaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.